Document is current

Article History

Received: 24 September 2025

Accepted: 7 November 2025

First Online: 7 December 2025

Declarations

:

: Editorial and medical writing assistance was provided under the direction of the authors by Crystal Murcia, PhD, and Pratibha Hebbar, PhD, of Synchrony Medical Communications, LLC, West Chester, PA, and was funded by Bausch + Lomb, Bridgewater, NJ, USA.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

: Julie Poteet reports serving on advisory boards for Bausch + Lomb. Cecelia Koetting reports serving as a speaker, consultant, researcher, and/or advisor for AbbVie, Alcon, Allergan, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder Healthcare, Dompé, Myze, Orasis Pharmaceuticals, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Théa Pharma, Trukera Medical, Twenty/Twenty Therapeutics, and Viatris. Priya S. Vakharia reports serving as an investigator for Alexion Pharmaceuticals, Allgenesis Biotherapeutics, Aviceda Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Kirwin, Kodiak Sciences, Kyoto Pharmaceutical Industries, Ocular Therapeutix, OcuTerra Therapeutics, Opthea, ONL Therapeutics, Recens Medical, Regenx Bio, Stealth BioTherapeutics, and Unity; a consultant for AbbVie, Alimera Sciences, Annexon Biosciences, Apellis Pharmaceuticals, Astellas Pharma, Bausch + Lomb, Bayer, Coherus, Genentech, Notal Vision, Novartis, Ocuphire Pharma, and Regeneron Pharmaceuticals; a speaker for Astellas Pharma, Bausch + Lomb, Genentech, Heidelberg, and Regeneron Pharmaceuticals; and being an equity/stockholder in Quad-C/Prism.